Brief: GSK And Spero Therapeutics Announce Exclusive License Agreement For Tebipenem HBR

Spero Therapeutics

22/09/2022 07:19

Sept 22 (Reuters) - Spero Therapeutics Inc  SPRO.O :
    * GSK AND SPERO THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE
AGREEMENT
FOR LATE-STAGE ANTIBIOTIC ASSET, TEBIPENEM HBR
    * SPERO THERAPEUTICS INC - GSK TO PURCHASE $9 MILLION IN
SHARES OF
SPERO COMMON STOCK
    * GSK AND SPERO THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE
AGREEMENT
FOR LATE-STAGE ANTIBIOTIC ASSET, TEBIPENEM HBR
    * SPERO THERAPEUTICS INC - UNDER TERMS OF LICENSE AGREEMENT,
SPERO
WILL RECEIVE AN UPFRONT PAYMENT OF $66 MILLION FOR GSK TO SECURE
RIGHTS TO MEDICINE

Source text for Eikon:  ID:nGNXc29d6k 
Further company coverage:  SPRO.O 
 ((Reuters.Briefs@thomsonreuters.com;;))